Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00736840 · ClinicalTrials.gov registry record · Phase 3
BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis
A Phase 3 study of Chronic Liver Disease, sponsored by Meridian Bioscience.
- Completed
- Registry status
- Phase 3
- Development phase
- 414
- Enrollment target
- 11
- Study locations
NCT00736840 is a Phase 3 study of Chronic Liver Disease that has completed, run by Meridian Bioscience. The registered enrollment target is 414 participants, above the 286-participant average among 5 other Chronic Liver Disease trials with a reported enrollment target (45% higher). The trial reports 11 study locations across 8 states.
The verdict
NCT00736840, a Phase 3 study of Chronic Liver Disease, has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 414 participants
- Enrollment target
- 11
- Study locations
Study Summary
This trial is a pivotal trial to validate the use of a 13 C labeled substrate called methacetin and the BreathID automatic breath testing system, for determination of cirrhosis in patients with chronic liver disease.
Conditions Studied
Interventions
- DEVICE c13 methacetin solution with breath analyzer
Study Locations (11)
Other
- Soroka Medical Center - Beersheba
- Carmel Medical Center - Haifa
- Hadassah Medical Center - Jerusalem
Virginia
- Inova Helath System - Falls Church
- Virginia Commonwealth University Medical Center - Richmond
California
- Cedars Sinai Medical Center - Los Angeles
Michigan
- Henry Ford Health Sytem - Detroit
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania Health System - Philadelphia
South Carolina
- Medical University of South Carolina - Charleston
Texas
- St Luke's Episcopal Hospital, Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 414 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00736840
The ClinicalTrials.gov registry entry for NCT00736840 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 414 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 286-participant average among 5 other Chronic Liver Disease trials with a reported enrollment target (45% higher). The listed sponsor is Meridian Bioscience, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Liver Disease appearing as the primary indexed condition, and to 1 intervention - of which c13 methacetin solution with breath analyzer is the first listed.
NCT00736840 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Other, Virginia, California.
Frequently Asked Questions
What is clinical trial NCT00736840 about?
NCT00736840 is a clinical study titled "BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis". This trial is a pivotal trial to validate the use of a 13 C labeled substrate called methacetin and the BreathID automatic breath testing system, for determination of cirrhosis in patients with chronic liver disease.
What is the current status of trial NCT00736840?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 414 participants. The study started on 2008-08. Estimated completion is 2009-09.
What conditions does trial NCT00736840 study?
This clinical trial studies the following conditions: Chronic Liver Disease.
What interventions are being tested in trial NCT00736840?
The interventions under investigation include: c13 methacetin solution with breath analyzer (DEVICE).
Who is sponsoring clinical trial NCT00736840?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00736840 being conducted?
This trial has 11 study locations across California, Michigan, Ohio, Pennsylvania, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Endoscopic Ultrasound Shear Wave Elastography Study
RECRUITING
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
-
Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.